| UPDATE | 01.00 |
| CORP. ACQUISITION |
Aventis Pharmaceutical acquired Ariad Pharma.'s 50% inte rest in the Hoechst-Ariad Genomics Center. Ariad received - $40 million in cash, the return of 3 million shares of Ariad preferred stock, & forgiveness of $2 million of long-term debt held by Aventis - In addition, Ariad will receive osteoporosis drug candida tes & related technologies in which Hoechst Marion Rou ssel (predecessor of Aventis Pharma) invested $31 million as well as rights to certain genomics & bioinformatics tech nologies The Center will be renamed - AVENTIS CAMBRIDGE GENOMICS CENTER |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |